CerMed International Announces the Commencement of the CerCap Clinical Trial
(Thomson Reuters ONE) -
CerMed International /
CerMed International Announces the Commencement of the CerCap Clinical Trial
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Monterey, CA - December 13, 2011 - CerMed International (Frankfurt Stock
Exchange: CRX), an international women's medical device company, announced today
that an initial clinical trial for its CerCap device, a multipurpose, drug-
eluting cervical barrier cap that provides the dual benefits of contraception
and a reduction of the risk of infection with HIV, will begin January 2012 in
Zimbabwe. The University of Zimbabwe, College of Health Sciences, Department of
Obstetrics and Gynecology has recently received authorization, from both the
Medicines Control (MCAZ) and the Medical Research (MRCZ) Authorities of
Zimbabwe, to conduct a Phase I safety and acceptability clinical trial, on the
long term continuous use of the Company's CerCap, cervical barrier cap, in women
over a 21 day period.
The contribution of unwanted pregnancy to female mortality worldwide, along with
the devastating consequences of the HIV epidemic to women of reproductive age,
urges a convergence in pregnancy and HIV prevention. The intravaginal placement
of the CerCap device for a period of 21 days will provide a unique option for
women, especially in areas of the world where HIV and AIDS are rampant, by
combining long-term protection against unplanned pregnancy and a reduction in
the risk of HIV infection. CerMed is working closely with researchers in
Obstetrics and Gynecology at the University of California in San Francisco and
the University of Zimbabwe on this project.
Drew Hofmann, Executive VP & COO of the Company, stated: "We are excited to kick
off this initial clinical trial for our CerCap device in Zimbabwe. To our
knowledge, there are currently no dual purpose, women controlled contraceptive
products available that can provide both contraception and the reduction in the
risk of contracting HIV infection except for condoms (male and female), and none
offering protection from transmission of STDs, including HIV, via vaginally
administered drugs."
The trial is expected to begin in January 2012 and last for up to six months.
About CerMed International
CerMed International, Inc. is an international medical device company with
several breakthrough products addressing global women's health issues. These
lower cost products will aid in reducing the risk of female reproductive
diseases. They will enable women's health initiatives to be brought to the
underserved regions of the world and empower women to personally take steps to
reduce the risk of HIV and other STDs.
Forward Looking Statements Related to CerMed International
This press release contains forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause actual results or
experience to differ materially from that expressed or implied by the forward-
looking statements. Some of these risks and uncertainties include, but are not
limited to, (1) the economic circumstances surrounding CerMed's business,
including general economic conditions worldwide; (2) competitive pressures and
developments; (3) applicable laws and regulations; (4) the success or failure of
product development programs; (5) actions of regulatory authorities and the
timing thereof; (6) changes in exchange rates; (7) claims or concerns regarding
the safety or efficacy of marketed products or product candidates in
development; and (8) integration activities with acquired companies.
The forward-looking statements contained in this press release speak only as of
the date of this press release, and CerMed undertakes no obligation to revise or
update any forward-looking statements to reflect new information, future events
or circumstances after the date of the forward-looking statement. If CerMed does
update or correct one or more of these statements, investors and others should
not conclude that CerMed will make additional updates or corrections.
For further information please contact: German contact:
CerMed International MC Services AG
+1-831-920-2275-0 +49-89-210228-0
info(at)cermedint.com contact(at)mc-services.eu
www.cermedint.com
Press Release PDF :
http://hugin.info/148717/R/1570874/488532.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CerMed International via Thomson Reuters ONE
[HUG#1570874]
Unternehmensinformation / Kurzprofil:
Datum: 13.12.2011 - 09:53 Uhr
Sprache: Deutsch
News-ID 96235
Anzahl Zeichen: 5529
contact information:
Town:
Monterey CA
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CerMed International Announces the Commencement of the CerCap Clinical Trial"
steht unter der journalistisch-redaktionellen Verantwortung von
CerMed International (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
